Kristina Burow

Kristina Burow is behind 26 open-market purchases, 87% of the market trades in this record of 103 filings published between August 1, 2017 and July 6, 2026. For the 13 purchases with a reported amount, the total reaches EUR 30,192,885, with a median of EUR 696,692. The largest, EUR 13,876,125, is dated February 3, 2025 at Metsera, Inc.; next come EUR 4,298,580 at Neumora Therapeutics, Inc. (October 27, 2025) and EUR 4,112,224 at Sienna Biopharmaceuticals, Inc. (February 22, 2019).

Burow serves as a Director at ten US companies. Neumora Therapeutics, Inc. weighs most with 29 filings and 19 purchases, ahead of Beam Therapeutics Inc. (20), Scholar Rock Holding Corp (18) and Metsera, Inc. (8). The record's 4 sales, EUR 285,246 in all, are all at Scholar Rock Holding Corp; the biggest is EUR 115,352 (May 29, 2025). The record also holds 65 filings of another kind, 4 grants and 4 option exercises.

The peak is 29 filings in 2023. Filings are published a median of 1 day after the trade. The last twelve months hold 13 filings, with 1 purchase and 2 sales.

At Neumora Therapeutics, 18 of Burow's own trades fall within 30 days of a trade by ARCH Venture Partners XII, LLC, all in the same direction, and 8 do so for Henry O. Gosebruch.